ALPHA 1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Inhaled therapy aims to halt lung decline in rare genetic disease
Disease control Recruiting nowThis study tests whether daily inhaled AAT (a protein) can slow lung function loss in people with Alpha-1 antitrypsin deficiency, a genetic condition that causes emphysema. About 220 adults with moderate to severe lung disease will receive either the drug or a placebo for 2 years…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Kamada, Ltd. • Aim: Disease control
Last updated May 17, 2026 11:38 UTC
-
One-Time gene therapy could shield lungs in rare disease
Disease control Recruiting nowThis early-stage study tests a gene therapy for people with alpha-1 antitrypsin deficiency, a condition that can damage the lungs. The treatment is given once through a vein and aims to produce a special protein that protects the lungs. The study will check for safety and side ef…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New injection aims to fix lung and liver protein deficiency
Disease control Recruiting nowThis early-stage study tests a new drug called AIR-001 in 54 adults with Alpha-1 Antitrypsin Deficiency (AATD) who have the PiZZ genetic type. The goal is to see if the drug is safe and can raise levels of a protective protein that is missing in these patients. Participants recei…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: AIRNA Corporation • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
Gene editing breakthrough targets rare lung and liver disease
Disease control Recruiting nowThis study tests a new gene editing medicine called BEAM-302 for adults with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung and liver damage. The treatment aims to fix the faulty gene to raise protective protein levels and reduce disease progressio…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1, PHASE2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Massive study seeks 50,000 volunteers to unlock secrets of rare lung and liver disease
Knowledge-focused Recruiting nowThis study aims to learn more about Alpha-1 Antitrypsin Deficiency, a genetic condition that can affect the lungs and liver. Researchers will follow up to 50,000 people who are at risk due to symptoms or family history. Participants will fill out questionnaires to help track how …
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated May 14, 2026 12:11 UTC
-
New study aims to uncover hidden lung damage in Alpha-1 carriers
Knowledge-focused Recruiting nowThis study looks at 80 adults with a specific genetic type of alpha-1 antitrypsin deficiency (PiMZ) who also have COPD. Researchers will use CT scans over three years to measure lung density changes and find better ways to track the disease. The goal is to develop tools that can …
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC
-
Researchers probe how two lung diseases disable immune cells
Knowledge-focused Recruiting nowThis study looks at how Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis affect white blood cells in the lungs called macrophages. Researchers will collect blood samples from 220 adults to measure how well these cells work. The goal is to better understand these diseases, not t…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated May 04, 2026 16:23 UTC